| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Mineralys Therapeutics (NASDAQ:MLYS) through any online brokerage.
Other companies in Mineralys Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Mineralys Therapeutics has a consensus price target of $48.67.
The stock price for Mineralys Therapeutics (NASDAQ: MLYS) is $21.99 last updated October 7, 2026 at 5:50 AM EDT.
There are no upcoming dividends for Mineralys Therapeutics.
Mineralys Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Mineralys Therapeutics.
Mineralys Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
